Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,621 to 2,640 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Betamethasone vs Placebo: Number of Neonates With Hypoglycemia | 343 of 1,427 210 of 1,400 | 9.0 points 6.1 to 11.9 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates With Transient Tachypnea of the Newborn | 95 of 1,427 138 of 1,400 | -3.2 points -5.2 to -1.2 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Neonatal Outcome Composite | 198 of 1,427 249 of 1,400 | -3.9 points -6.6 to -1.2 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates With Respiratory Distress Syndrome | 79 of 1,427 89 of 1,400 | -0.8 points -2.6 to 0.9 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Neonatal Death After 72 Hours of Delivery | 2 of 1,427 0 of 1,400 | 0.1 points -0.2 to 0.5 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen | 2 of 1,427 9 of 1,400 | -0.5 points -1.1 to -0.0 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Neonatal Hyperbilirubinemia | 167 of 1,427 140 of 1,400 | 1.7 points -0.6 to 4.0 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Counselor vs Provider: Test Acceptance Rate | 1,382 of 1,959 643 of 861 | -4.1 points -7.6 to -0.5 | 2,820 | NCT00502944 Two Approaches to Routine HIV Testing in a Hospital Emergency Department |
| Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: deaths from any cause | 557 of 1,409 558 of 1,409 | -0.1 points -3.7 to 3.5 | 2,818 | NCT00773513 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) |
| Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: serious adverse events | 1,123 of 1,409 1,097 of 1,409 | 1.8 points -1.2 to 4.9 | 2,818 | NCT00773513 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) |
| Neratinib vs Placebo: serious adverse events | 103 of 1,408 85 of 1,408 | 1.3 points -0.6 to 3.1 | 2,816 | NCT00878709 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer |
| Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: Death at 90 Days | 166 of 1,394 170 of 1,421 | -0.1 points -2.5 to 2.3 | 2,815 | NCT00716079 The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial |
| Betamethasone vs Placebo: Neonates Needing Immediate Resuscitation After Birth | 206 of 1,422 260 of 1,390 | -4.2 points -7.0 to -1.5 | 2,812 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Arm I (Aspirin) vs Arm II (Placebo): serious adverse events | 99 of 1,393 91 of 1,415 | 0.7 points -1.2 to 2.6 | 2,808 | NCT02927249 Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
| Benlysta vs Non-Benlysta: deaths from any cause | 48 of 1,924 29 of 881 | -0.8 points -2.3 to 0.5 | 2,805 | NCT01729455 Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry |
| Benlysta vs Non-Benlysta: serious adverse events | 248 of 1,924 108 of 881 | 0.6 points -2.1 to 3.2 | 2,805 | NCT01729455 Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to an Event of Discontinuation of Initial Therapy Occurring in a Year | 374 of 1,396 219 of 1,403 | 11.2 points 8.2 to 14.2 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to the First Serious Adverse Event of Pneumonia Occuring in a Year | 89 of 1,396 80 of 1,403 | 0.7 points -1.1 to 2.5 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Non-serious Adverse Drug Reactions (ADR) | 192 of 1,396 88 of 1,403 | 7.5 points 5.3 to 9.7 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year | 852 of 1,396 943 of 1,403 | -6.2 points -9.7 to -2.6 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=132"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=132
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01222247-bcdd4e8c",
"title": "Betamethasone vs Placebo: Number of Neonates With Hypoglycemia",
"summary": "343 of 1427 against 210 of 1400; risk difference 9.0 points, 95% interval 6.1 to 11.9; NCT01222247, Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial",
"record": "/library/comparisons/NCT01222247-bcdd4e8c",
"nct_id": "NCT01222247",
"kind": "outcome",
"participants": 2827,
"risk_difference": {
"value": 0.09036440084092504,
"lower": 0.06126376060509434,
"upper": 0.11929466822040527
},
"group_1": "343 of 1,427",
"group_2": "210 of 1,400",
"difference": "9.0 points",
"interval": "6.1 to 11.9",
"trial_title": "Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial"
},
{
"id": "NCT01222247-c45a693f",
"title": "Betamethasone vs Placebo: Number of Neonates With Transient Tachypnea of the Newborn",
"summary": "95 of 1427 against 138 of 1400; risk difference -3.2 points, 95% interval -5.2 to -1.2; NCT01222247, Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial",
"record": "/library/comparisons/NCT01222247-c45a693f",
"nct_id": "NCT01222247",
"kind": "outcome",
"participants": 2827,
"risk_difference": {
"value": -0.0319981980178196,
"lower": -0.052473972845713895,
"upper": -0.01172659273487213
},
"group_1": "95 of 1,427",
"group_2": "138 of 1,400",
"difference": "-3.2 points",
"interval": "-5.2 to -1.2",
"trial_title": "Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=133",
"request_id": "hJNc4V_Qb_YIncQ8"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant